Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02780115 · ClinicalTrials.gov registry record · Phase 2
A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT02780115 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 151 participants.
The verdict
NCT02780115, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
This is a safety, efficacy and pharmacokinetics study of the fixed combination of AGN-199201 and AGN-190584 in participants with presbyopia (inability to focus on items close-up).
Interventions
- DRUG AGN-199201 Vehicle
- DRUG AGN-199201 ophthalmic solution
- DRUG AGN-190584 ophthalmic solution
- DRUG AGN-190584 Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2016-05-26 |
| Est. Completion | 2017-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02780115
The ClinicalTrials.gov registry entry for NCT02780115 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which AGN-199201 Vehicle is the first listed.
NCT02780115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02780115 about?
NCT02780115 is a clinical study titled "A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia". This is a safety, efficacy and pharmacokinetics study of the fixed combination of AGN-199201 and AGN-190584 in participants with presbyopia (inability to focus on items close-up).
What is the current status of trial NCT02780115?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2016-05-26. Estimated completion is 2017-10-31.
What interventions are being tested in trial NCT02780115?
The interventions under investigation include: AGN-199201 Vehicle (DRUG), AGN-199201 ophthalmic solution (DRUG), AGN-190584 ophthalmic solution (DRUG), AGN-190584 Vehicle (DRUG).
Who is sponsoring clinical trial NCT02780115?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.